Clinical trials
Recherche d’études cliniques
Recherchez uniquement dans les études cliniques enregistrées dans Biomedical Watch.
Études cliniques 242
| Étude / NCT ⇅ | Molécule ⇅ | Maladie ⇅ | Phase ⇅ | Statut ⇅ | Résultat ⇅ | Sponsor ⇅ | Pays / centres ⇅ | Période ⇅ | Détail |
|---|---|---|---|---|---|---|---|---|---|
| NCT06314282 INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anif… |
INTERSTELLAR - International Stud… | Lupus | À vérifier | RECRUITING | En attente / non publié | AstraZeneca | Argentina, China, Costa Rica, Egypt, Guatemala, Kazak… | 2024-10-22 → 2027-12-31 | Ouvrir |
| NCT07570862 RECLAIM-LN — A Phase 2, Open-Label, Single-Arm Trial of FT819 in Partic… |
FT819 | Lupus | Phase 2 | RECRUITING | En attente / non publié | Fate Therapeutics | United States · Cross Creek Medical Clinic, Fayettevi… | 2026-07-27 → 2030-01-31 | Ouvrir |
| NCT06581198 A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus… |
rapcabtagene autoleucel | Lupus | Phase 2 | ACTIVE_NOT_RECRUITING | En attente / non publié | Novartis Pharmaceuticals | United States, Argentina, Australia, Austria, Brazil,… | 2024-09-04 → 2032-02-06 | Ouvrir |
| NCT07215663 Clinical Study of Cizutamig in Systemic Lupus Erythematosus |
Cizutamig | Lupus | Phase 1 | RECRUITING | En attente / non publié | Candid Therapeutics | China · Chinese Academy of Medical Sciences and Pekin… | 2025-09-04 → 2028-04 | Ouvrir |
| NCT06659029 PRIMULA_Preg — Prospective Registry Investigating Maternal and Infant O… |
Anifrolumab | Lupus | À vérifier | RECRUITING | En attente / non publié | University of Cambridge | United States · Research Site, Wilmington, United Sta… | 2025-07-01 → 2031-04-15 | Ouvrir |
| NCT07791199 Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric PsO… |
Deucravacitinib | Lupus | Phase 3 | NOT_YET_RECRUITING | En attente / non publié | Bristol-Myers Squibb | Non communiqué | 2026-12-31 → 2030-10-31 | Ouvrir |
| NCT02633163 Phase 2 Trial of Mesenchymal Stem Cells in Systemic Lupus Erythematosus… |
Low Dose Mesenchymal Stem Cells (… | Lupus | Phase 2 | COMPLETED | En attente / non publié | Medical University of South Carol… | United States · Cedars-Sinai Medical Center, Los Ange… | 2018-11-18 → 2026-02-03 | Ouvrir |
| NCT06711887 Phase III Extension Study of Efficacy and Safety of Ianalumab With or W… |
Ianalumab | Lupus | Phase 3 | RECRUITING | En attente / non publié | Novartis Pharmaceuticals | United States, Brazil, China, Colombia, Czechia, Fran… | 2025-05-19 → 2035-08-01 | Ouvrir |
| NCT07783711 Predictors of ICU Admission and In-Hospital Mortality in Hospitalized P… |
Predictors of ICU Admission and I… | Lupus | À vérifier | NOT_YET_RECRUITING | En attente / non publié | Khaled Samir Malak Nashed | Non communiqué | 2026-09 → 2028-10-01 | Ouvrir |
| NCT07767188 A Trial to Explore the Efficacy and Safety of O-triple as Initial Thera… |
obinutuzumab (RO5072759) | Lupus | Phase 3 | NOT_YET_RECRUITING | En attente / non publié | Zhao Minghui | China · Fujian Medical University Union Hospital, Fuz… | 2026-09-10 → 2029-05-08 | Ouvrir |
| NCT06121297 RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Effi… |
CABA-201 | Lupus | Phase 1/2 | RECRUITING | En attente / non publié | Cabaletta Bio | United States, Canada, Spain · Boston Children's Hosp… | 2024-02-16 → 2029-12 | Ouvrir |
| NCT05001737 EMERALD — Evaluate Efficacy, Safety and Tolerability, PK and PD of Emap… |
Emapalumab | Lupus | Phase 3 | COMPLETED | En attente / non publié | Swedish Orphan Biovitrum | United States, Belgium, Canada, China, Czechia, Franc… | 2021-12-15 → 2025-06-04 | Ouvrir |
| NCT05818254 HOP-STEPsIRB — The HOP-STEP Intervention: Improving Maternal Health in … |
HOP-STEPsIRB — The HOP-STEP Inter… | Lupus | Non applicable | COMPLETED | En attente / non publié | Duke University | United States · University of Chicago Medical Center,… | 2024-10-07 → 2026-07-31 | Ouvrir |
| NCT07323173 A Study to Assess the Safety and PK/PD of LBL-047 in Healthy Adults and… |
LBL-047 for Injection | Lupus | Phase 1 | RECRUITING | En attente / non publié | Nanjing Leads Biolabs Co.,Ltd | China · Beijing GoBroad Hospital, Beijing, China | Mi… | 2025-12-16 → 2027-12-16 | Ouvrir |
| NCT07053800 LUMINA — Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SL… |
Obecabtagene autoleucel | Lupus | Phase 2 | RECRUITING | En attente / non publié | Autolus Limited | United States, Brazil, Greece, United Kingdom, Vietna… | 2026-01-16 → 2029-10 | Ouvrir |
| NCT06980805 A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 i… |
IMVT-1402 | Lupus | Phase 2 | ACTIVE_NOT_RECRUITING | En attente / non publié | Immunovant Sciences GmbH | United States, Argentina, Bulgaria, Canada, Chile, Ge… | 2025-02-19 → 2027-04 | Ouvrir |
| NCT07424261 VIOLET — NIS to Examine Disease Activity in SLE Patients Treated With S… |
VIOLET — NIS to Examine Disease A… | Lupus | À vérifier | RECRUITING | En attente / non publié | AstraZeneca | Germany · Research Site, Altenburg, Germany | Researc… | 2026-03-19 → 2029-08-31 | Ouvrir |
| NCT06513429 IM19 CAR-T Cell Therapy in Refractory Systemic Lupus Erythematosus (SLE) |
IM19 CAR-T cells | Lupus | Non applicable | RECRUITING | En attente / non publié | Peking University Third Hospital | China · Peking Universitiy Third Hospital, Beijing, C… | 2024-07-30 → 2027-12-31 | Ouvrir |
| NCT06342960 KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR… |
KYV-101 anti-CD19 CAR-T cell ther… | Lupus | Phase 1/2 | TERMINATED | En attente / non publié | Kyverna Therapeutics | Germany · Charite- Universitätsklinikum Berlin, Berli… | 2022-12-01 → 2025-12-22 | Ouvrir |
| NCT05938725 KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR… |
KYV-101 anti-CD19 CAR-T cell ther… | Lupus | Phase 1/2 | TERMINATED | En attente / non publié | Kyverna Therapeutics | United States · Northwell Health, Great Neck, United … | 2023-04-28 → 2026-05-29 | Ouvrir |
| NCT01399411 Agricultural Health Study Follow-up |
Agricultural Health Study Follow-… | Parkinson | À vérifier | COMPLETED | En attente / non publié | National Institute of Environment… | United States · Batelle, Inc., Columbus, United State… | 2011-07-05 | Ouvrir |
| NCT04767698 Addition of Belimumab to B-cell Depletion in Relapsing-remitting Multip… |
Belimumab | SEP | Phase 2 | TERMINATED | En attente / non publié | Johns Hopkins University | United States · Johns Hopkins University, Baltimore, … | 2021-10-01 → 2022-05-10 | Ouvrir |
| NCT07680010 PRELUDE — Modeling the Early Stages of Autoimmunity Through the Study o… |
Blood sampling baseline and M3 | Lupus | Non applicable | NOT_YET_RECRUITING | En attente / non publié | University Hospital, Bordeaux | France · Chu de Bordeaux- Groupe Hospitalier Pellegri… | 2026-07 → 2033-10 | Ouvrir |
| NCT07393399 SLE-OMEGA — Omega-3 Supplementation in Systemic Lupus Erythematosus |
SLE-OMEGA — Omega-3 Supplementati… | Lupus | Non applicable | NOT_YET_RECRUITING | En attente / non publié | University of Sao Paulo | Non communiqué | 2026-07 → 2028-07 | Ouvrir |
| NCT07237659 LIBERATE-I — Phase 1a/b Tolerability of NTR-1011 in Healthy Adults and … |
NTR1011 | Lupus | Phase 1 | RECRUITING | En attente / non publié | Neutrolis | United States · Attune Health Research Inc, Beverly H… | 2026-07-15 → 2027-08-31 | Ouvrir |